secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2026-08-06T20:10:59+00:00
Accession:  0001193125-26-338006
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Definium Therapeutics Q2 net loss $159M; Phase 3 Emerge MDD study meets primary endpoint
--------------------------------------------------------------------------------

- Phase 3 Emerge in MDD met primary endpoint: 8.1-point MADRS improvement vs placebo at Week 6 (p<0.0001).
- Cash, equivalents and investments $1.1B as of June 30, 2026, up from $411.6M at Dec 31, 2025.
- Net loss $159.0M for Q2 2026 vs $42.7M in Q2 2025, including $86.2M non-cash warrant liability charge.
- R&D expenses $48.7M, G&A $26.4M; completed public offering of $805M gross proceeds.
- Topline GAD results from Voyage expected week of Aug 10; Panorama in Sept 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/0001193125-26-338006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/dftx-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer